Page 179 - பல்கலைக்கழகம் ஆஃப் நாட்டிங்ஹாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Editas Medicine Names Mark S Shearman, Ph D , as Chief Scientific Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 05, 2021
Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end
RUBY trial of EDIT-301 for sickle cell disease active and recruiting
Preclinical ocular data presented at ARVO supports in vivo gene editing
$723 million
as of March 31, 2021
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the first quarter of 2021.
“Our team is making tremendous progress towards discovering, developing, and manufacturing novel genome editing medicines, including excellent forward momentum this quarter for our two clinical-stage medicines,” said James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine. “We are pleased to announce Dr. Mark Shearman will be joining Editas as Chief Scientific Officer in June 2021. Mark has an outstanding track record of drug discovery and development
Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer
May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Company’s pipeline of experimental medicines
.
“We are delighted to have Mark join our team in June. Mark has an outstanding track record of drug discovery and development and leading high performing teams. Specifically, during his career, he has led discovery programs across multiple modalities, including ophthalmology, immunology, and neurology – key areas of focus for E
Fury over Champions League final plans that could see 8,000 Man City and Chelsea fans travel to Covid hotspot Turkey as MPs warn move would make a mockery of Britain s lockdown efforts and demand UEFA moves the game to the UK
Champions League final is set to be played at Ataturk Stadium in Istanbul, Turkey, on May 29
Sources told The Times that 25,000 fans are expected to attend the game with many travelling internationally
Covid infection rates are 12 times higher in Turkey than the UK with 31,000 new cases yesterday
Labour MP and football fan, Clive Efford, says allowing fans to travel would make a mockery of UK s effort
E-Mail
Some clinicians are concerned that post-traumatic stress disorder (PTSD) diagnosis has risen throughout Western society since the late 1980s. Is this correct? And if so, has the true incidence of PTSD really spiralled out of control, or has it simply become overdiagnosed?
Experts debate the issue in
The BMJ this week.
PTSD is a serious and uncommon condition resulting from severe trauma, but it has unhelpfully become an umbrella term incorporating other disorders and normal reactions to stress, argue John Tully at the University of Nottingham and Dinesh Bhugra at King s College London s Institute for Psychiatry, Psychology & Neuroscience (IoPPN).
vimarsana © 2020. All Rights Reserved.